<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AURYXIA- tetraferric tricitrate decahydrateÂ tablet, coatedÂ </strong><br>Keryx Biopharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use AURYXIA safely and effectively.  See full prescribing information for AURYXIA.
			<br><br>AURYXIA (ferric citrate) tablets,  for oral use
		<br>Initial U.S. Approval:  2014
	</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Auryxiaâ„¢  is a phosphate binder indicated for the control of serum phosphorus levels in patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> on dialysis (<a href="#a472483-f897-1">1</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Starting dose is 2 tablets orally 3 times per day with meals  (<a href="#a472483-f897-2">2</a>)</li>
<li>Adjust dose by 1 to 2 tablets as needed to maintain serum phosphorus at target levels, up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals. (<a href="#a472483-f897-2">2</a>)</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Tablets: 210 mg ferric iron, equivalent to 1 g ferric citrate (<a href="#a472483-f897-3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li><span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">Iron overload</span> syndromes (e.g., <span class="product-label-link" type="condition" conceptid="4163735" conceptname="Hemochromatosis">hemochromatosis</span>) (<a href="#a472483-f897-4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">Iron overload</span>: Monitor ferritin and TSAT. Patients may require a reduction in dose or discontinuation of IV iron. (<a href="#a472483-f897-5-1">5.1</a>)</li>
<li>Accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of iron-containing products is a leading cause of fatal <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> in children under 6 years of age.  Keep this product out of reach of children.  In case of accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call a doctor or poison control center immediately.  (<a href="#a472483-f897-5-2">5.2</a>)</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>: Safety has not been established. (<a href="#a472483-f897-5-3">5.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul><li>In clinical trials, likely adverse reactions occurring with Auryxia included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, discolored feces, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (<a href="#a472483-f897-6-1">6.1</a>)</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact  Keryx Biopharmaceuticals at 1-844-445-3799 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>When clinically significant drug interactions are expected, consider separation of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medication (<a href="#a472483-f897-7">7</a>)</li></ul></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Dosing and Dose Adjustment</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 	<span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">Iron Overload</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 	Accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of Iron</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 	Patients with <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal Bleeding</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 	Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2  Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5  Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Long-term, Randomized, Controlled, Safety and Efficacy Trial</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 	Fixed-Dose Trial</a></h2>
<h1><a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1	How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2	Storage and Handling</a></h2>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Dosing Recommendations</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Adverse Reactions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="a472483-f897-1"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">Auryxia (ferric citrate) is a phosphate binder indicated for the control of serum phosphorus levels in patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> on dialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="a472483-f897-2"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="a472483-f897-2-1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Dosing and Dose Adjustment</h2>
<p class="First">The recommended starting dose is 2 tablets orally 3 times per day with meals. Serum phosphorus levels should be monitored and the dose of Auryxia titrated in decrements or increments of 1 to 2 tablets per day as needed to maintain serum phosphorus at target levels, up to a maximum dose of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.</p>
<p>In a clinical trial conducted in the United States, patients required an average of 8 to 9 tablets a day to control serum phosphorus levels.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="a472483-f897-3"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Tablet:  Auryxia 210 mg ferric iron, equivalent to 1 g ferric citrate, film-coated, peach-colored, and oval-shaped tablet embossed with â€œKX52â€?.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="a472483-f897-4"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">Auryxia is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> syndromes (e.g., <span class="product-label-link" type="condition" conceptid="4163735" conceptname="Hemochromatosis">hemochromatosis</span>) <span class="Italics">[see Warnings and Precautions (<a href="#a472483-f897-5-1">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="a472483-f897-5"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="a472483-f897-5-1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 	<span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">Iron Overload</span></h2>
<p class="First">Iron absorption from Auryxia may lead to excessive elevations in iron stores. Increases in serum ferritin and <span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span> (TSAT) levels were observed in clinical trials. In a 56-week safety and efficacy trial in which concomitant use of Auryxia and IV iron was permitted, 55 (19%) of patients treated with Auryxia had a ferritin level &gt;1500 ng/mL as compared with 13 (9%) of patients treated with active control.</p>
<p>Assess iron parameters (e.g., serum ferritin and TSAT) prior to initiating Auryxia and monitor iron parameters while on therapy <span class="Italics">[see Contraindications (<a href="#a472483-f897-4">4</a>), Overdosage (<a href="#a472483-f897-10">10</a>) and Clinical Pharmacology (<a href="#a472483-f89712-2-">12.2</a>)]</span>.  Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a472483-f897-5-2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 	Accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of Iron</h2>
<p class="First">Accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of iron-containing products is a leading cause of fatal <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> in children under 6 years of age. Keep this product out of the reach of children. In case of accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call a doctor or poison control center immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a472483-f897-5-3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 	Patients with <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal Bleeding</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> or active, symptomatic <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> were excluded from clinical trials. Safety has not been established in these populations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a472483-f897-6"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="a472483-f897-6-1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to adverse reaction rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Adverse <span class="Italics">reactions</span> to a drug are most readily ascertained by comparison with placebo, but there is little placebo-controlled experience with Auryxia, so this section describes adverse <span class="Italics">events</span> with Auryxia, some of which may be disease-related, rather than treatment-related.</p>
<p>A total of 289 patients were treated with Auryxia and 149 patients were treated with active control (sevelamer carbonate and/or calcium acetate) during the 52-week, randomized, open-label, active control phase of a trial in patients on dialysis. A total of 322 patients were treated with Auryxia for up to 28 days in three short-term trials. Across these trials, 557 unique patients were treated with Auryxia; dosage regimens in these trials ranged from 210 mg to 2,520 mg of ferric iron per day, equivalent to 1 to 12 tablets of Auryxia. In these trials, adverse events reported for Auryxia were similar to those reported for the active control group.</p>
<p>Adverse events reported in more than 5% of patients treated with Auryxia in these trials included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (21%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (11%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (8%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (7%), and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (6%).</p>
<p>During the 52-week, active-control period, 60 patients (21%) on Auryxia discontinued study drug because of an adverse event, as compared to 21 patients (14%) in the active control arm. Patients who were previously intolerant to any of the active control treatments (calcium acetate and sevelamer carbonate) were not eligible to enroll in the study.  Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia (14%).</p>
<p>Auryxia is associated with discolored feces (dark stools) related to the iron content, but this staining is not clinically relevant and does not affect laboratory tests for occult <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which detect heme rather than non-heme iron in the stool.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="a472483-f897-7"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<a name="table1"></a><table cellpadding="7" class="Noautorules" width="500">
<col width="30%">
<col width="70%">
<tbody class="Headless">
<tr><td class="Botrule Lrule Rrule Toprule" colspan="2" valign="middle"><span class="Bold">Table 1: Oral drugs that can be administered concomitantly with Auryxia</span></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="2">Amlodipine<br>
									Aspirin<br>
									Atorvastatin<br>
									Calcitriol<br>
									Clopidogrel<br>
									Digoxin<br>
									Diltiazem<br>
									Doxercalciferol<br>
									Enalapril<br>
									Fluvastatin<br>
									Glimepiride<br>
									Levofloxacin<br>
									Losartan<br>
									Metoprolol<br>
									Pravastatin<br>
									Propranolol<br>
									Sitagliptin<br>
									Warfarin<br>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Oral drugs that have to be separated from Auryxia and meals</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Dosing Recommendations</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Doxycycline</td>
<td class="Botrule Lrule Rrule Toprule">Take at least 1 hour before Auryxia</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Ciprofloxacin</td>
<td class="Botrule Lrule Rrule Toprule">Take at least 2 hours before or after Auryxia</td>
</tr>
</tbody>
</table>
<p class="First"><span class="Italics">Oral medications not listed in <a href="#table1">Table 1</a></span></p>
<p>There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs. For oral medications where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, consider separation of the timing of the administration of the two drugs. The duration of separation depends upon the absorption characteristics of the medication concomitantly administered, such as the time to reach peak systemic levels and whether the drug is an immediate release or an extended release product.  Consider monitoring clinical responses or blood levels of concomitant medications that have a narrow therapeutic range.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="a472483-f897-8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="a472483-f897-8-1"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First">Pregnancy Category B:  There are no adequate and well-controlled studies in pregnant women.  It is not known whether Auryxia can cause fetal harm when administered to a pregnant woman.  Animal reproduction studies have not been conducted.</p>
<p>The effect of Auryxia on the absorption of vitamins and other nutrients has not been studied in pregnant women.  Requirements for vitamins and other nutrients are increased in pregnancy. An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of iron in pregnant women may carry a risk for <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>, <span class="product-label-link" type="condition" conceptid="4024659" conceptname="Gestational diabetes mellitus">gestational diabetes</span> and <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformation</span> <span class="Italics">[see Nonclinical Toxicology (<a href="#a472483-f897-13-1">13.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="a472483-f897-8-2"></a><a name="section-8.2"></a><p></p>
<h2>8.2  Labor and Delivery</h2>
<p class="First">The effects of Auryxia on labor and delivery are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="a472483-f897-8-3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Data from rat studies have shown the transfer of iron into milk by divalent metal transporter-1 (DMT-1) and ferroportin-1 (FPN-1). Hence, there is a possibility of infant exposure when Auryxia is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="a472483-f897-8-4"></a><a name="section-8.4"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">The safety and efficacy of Auryxia have not been established in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="a472483-f897-8-5"></a><a name="section-8.5"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">Clinical studies of Auryxia included 106 subjects aged 65 years and older (33 subjects aged 75 years and older).  Overall, the clinical study experience has not identified any obvious differences in responses between the elderly and younger patients in the tolerability or efficacy of Auryxia.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="a472483-f897-10"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">No data are available regarding <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of Auryxia in patients.  In patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> on dialysis, the maximum dose studied was 2,520 mg ferric iron (12 tablets of Auryxia) per day. Iron absorption from Auryxia may lead to excessive elevations in iron stores, especially when concomitant IV iron is used <span class="Italics">[see Warnings and Precautions (<a href="#a472483-f897-5-1">5.1</a>)]</span>.</p>
<p>In clinical trials, one case of elevated iron in the liver as confirmed by biopsy was reported in a patient administered IV iron and Auryxia.</p>
<p>Because accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of iron-containing products is a leading cause of fatal <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> in children under 6 years of age, this product must be kept out of the reach of children.  In case of accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a doctor or poison control center should be contacted immediately <span class="Italics">[see Warnings and Precautions (<a href="#a472483-f897-5-2">5.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="a472483-f897-11"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">Auryxia (ferric citrate) is known chemically as iron (+3), <span class="Italics">x</span> (1, 2, 3-propanetricarboxylic acid, 2 hydroxy-), <span class="Italics">y</span> (H<span class="Sub">2</span>O)</p>
<p><img alt="Ferric Citrate Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aadd18e0-3752-11e4-8510-0800200c9a66&amp;name=keryx-figure-1.jpg"></p>
<p>Auryxia 210 mg ferric iron tablets, equivalent to 1g ferric citrate, are film-coated, peach-colored, and oval-shaped tablets embossed with â€œKX52â€?.  The inactive ingredients are pregelatinized starch and calcium stearate.  In addition, the film-coating contains the following inactive ingredients; hypromellose, titanium dioxide, triacetin, and FD&amp;C Yellow #6/Sunset Yellow FCF Aluminum Lake, FD&amp;C Red #40/Allura Red AC Aluminum Lake, and FD&amp;C Blue #2/Indigo Carmine Aluminum Lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="a472483-f897-12"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="a472483-f897-12-1"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Ferric iron binds dietary phosphate in the GI tract and precipitates as ferric phosphate.  This compound is insoluble and is excreted in the stool.  By binding phosphate in the GI tract and decreasing absorption, ferric citrate lowers the phosphate concentration in the serum.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="a472483-f89712-2-"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics</h2>
<p class="First">In addition to effects on serum phosphorus levels, Auryxia has been shown to increase serum iron parameters, including ferritin, iron and TSAT.  In dialysis patients treated with Auryxia in a 52-week study in which IV iron could also be administered, mean (SD) ferritin levels rose from 593 (293) ng/mL to 895 (482) ng/mL, mean (SD) TSAT levels rose from 31% (11) to 39% (17) and mean (SD) iron levels rose from 73 (29) mcg/dL to 88 (42) mcg/dL. In contrast, in patients treated with active control, these parameters remained relatively constant <span class="Italics">[see Contraindications (<a href="#a472483-f897-4">4</a>) and Warnings and Precautions (<a href="#a472483-f897-5-1">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="a472483-f897-12-3"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption and Distribution</span></p>
<p>Formal pharmacokinetic studies have not been performed with Auryxia.  Examination of serum iron parameters has shown that there is systemic absorption of iron from Auryxia <span class="Italics">[see Contraindications (<a href="#a472483-f897-4">4</a>), Warnings and Precautions (<a href="#a472483-f897-5-1">5.1</a>) and Clinical Pharmacology (<a href="#a472483-f89712-2-">12.2</a>)]</span>.</p>
<p><span class="Italics">Drug Interaction Studies</span></p>
<p><span class="Italics">In vitro</span></p>
<p>Of the drugs screened for an interaction with ferric citrate in vitro, only doxycycline showed the potential for interaction with at least 70% decrease in its concentration.  This interaction can be avoided by spacing the administration of doxycycline and ferric citrate <span class="Italics">[see Drug Interactions (<a href="#a472483-f897-7">7</a>)]</span>. </p>
<p><span class="Italics">In vivo</span></p>
<p>Six drug interaction studies (N=26-60/study) were conducted to establish the effects of Auryxia (administered as 3 x 2 g/day with meals) on the disposition of concomitantly orally administered clopidogrel, ciprofloxacin, digoxin, diltiazem, glimepiride and losartan in healthy subjects. With the exception of ciprofloxacin, Auryxia did not alter the systemic exposure of the tested drugs, as measured by the area under the curve (AUC) and Cmax of the tested drugs when either co-administered with Auryxia or given 2 hours later. Auryxia decreased the relative bioavailability of concomitantly administered ciprofloxacin by approximately 45%. However, there was no interaction when Auryxia and ciprofloxacin were taken 2 hours apart. Consequently, ciprofloxacin should be taken at least 2 hours before or after Auryxia is dosed <span class="Italics">[see Drug Interactions (<a href="#a472483-f897-7">7</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="a472483-f897-13"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="a472483-f897-13-1"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Data from carcinogenesis studies have shown that ferric citrate is not carcinogenic in mice and rats when administered intramuscularly or subcutaneously. Ferric citrate was neither mutagenic in the bacterial reverse mutation assay (Ames test) nor clastogenic in the chromosomal aberration test in Chinese hamster fibroblasts.</p>
<p>The potential for ferric citrate to impair reproductive performance or to cause <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformation</span> has not been evaluated. Skeletal and encephalic malformation was observed in neonatal mice when ferric gluconate was administered intraperitoneally to gravid dams on gestation days 7-9. However, oral administration of other ferric or ferrous compounds to gravid CD1-mice and Wistar-rats caused no <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformation</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="a472483-f897-14"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First">The ability of Auryxia to lower serum phosphorus in patients with CKD on dialysis was demonstrated in randomized clinical trials: one 56-week, safety and efficacy trial, consisting of a 52-week active-controlled phase and a 4-week, placebo-controlled, randomized withdrawal period, and one 4-week open-label trial of different fixed doses of Auryxia.  Both trials excluded subjects who had an absolute requirement for aluminum containing drugs with meals.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="a472483-f897-14-1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Long-term, Randomized, Controlled, Safety and Efficacy Trial</h2>
<p class="First">After the 2-week washout period during which phosphate binders were held, patients with a mean serum phosphorus of 7.5 mg/dL during washout were randomized 2:1 to Auryxia (N=292) or active control (calcium acetate and/or sevelamer carbonate; N=149).  The majority (&gt;96%) of subjects were on hemodialysis.  The starting dose of Auryxia was 6 tablets/day, divided with meals.  The starting dose of active control was the patientâ€™s dose prior to the washout period. The dose of phosphate binder was increased or decreased as needed to maintain serum phosphorus levels between 3.5 and 5.5 mg/dL, to a maximum of 12 tablets/day.</p>
<p>As shown in the figure below, serum phosphorus levels declined following initiation of therapy. The phosphorus lowering effect was maintained over 52 weeks of treatment.</p>
<br><p><span class="Bold">Figure 1: Serum Phosphorus Control over 52 Weeks</span></p>
<p><img alt="Figure 1: Serum Phosphorus Control over 52 Weeks" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aadd18e0-3752-11e4-8510-0800200c9a66&amp;name=keryx-figure-2.jpg"></p>
<p>Following completion of the 52-week active-controlled phase, Auryxia-treated patients were eligible to enter a 4-week placebo-controlled randomized withdrawal phase, in which patients were re-randomized in a 1:1 ratio to receive Auryxia (N=96) or placebo (N=96). During the placebo-controlled period, the serum phosphorus concentration rose by 2.2 mg/dL on placebo relative to patients who remained on Auryxia.</p>
<table cellpadding="4" class="Noautorules" width="900">
<caption><span>Table 2:	Effect of Auryxia on serum phosphorus during randomized withdrawal</span></caption>
<tfoot><tr><td colspan="6">
<span class="Sup">a</span>Â The LS mean treatment difference and p-value for the change in mean were created via an ANCOVA model with treatment as the fixed effect and Week-52 baseline (phosphorus) as the covariate.  Between-treatment differences were calculated as the LS mean (KRX 0502) â€“ LS mean (placebo or active control).<br><br>Note:  Analyses using ANCOVA with last observation carried forward. ANCOVA=analysis of covariance; CI=confidence interval.</td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><span class="Bold">Primary Endpoint (Week 56)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Auryxia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Placebo</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><span class="Bold">Treatment Difference<br>(95% CI)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><span class="Bold">p-value</span></td>
</tr>
<tr>
<td class="Lrule" align="left">Serum phosphorus (mg/dL)</td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule" align="left">Â Â Â Â Â Â Mean baseline (Week 52)</td>
<td class="Lrule" align="center">5.12</td>
<td class="Lrule" align="center">5.44</td>
<td class="Lrule" align="left"></td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Â Â Â Â Â Â Mean change from baseline (Week 56)</td>
<td class="Botrule Lrule" align="center">-0.24</td>
<td class="Botrule Lrule" align="center">1.79</td>
<td class="Botrule Lrule" align="left">âˆ’2.18 (âˆ’2.59, âˆ’1.77)</td>
<td class="Botrule Lrule Rrule" align="left">&lt;0.0001<span class="Sup">a</span>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a472483-f897-14-2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 	Fixed-Dose Trial</h2>
<p class="First">Following a 1- to 2-week washout from all phosphate-binding agents, 154 patients with <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> (mean serum phosphorus of 7.5 mg/dL) and CKD on dialysis were randomized in a 1:1:1 ratio to 1, 6, or 8 tablets/day of Auryxia for 4 weeks. Auryxia was administered with meals; subjects receiving 1 tablet/day were instructed to take it with their largest meal of the day, and subjects on 6 or 8 tablets/day took divided doses in any distribution with meals. Dose-dependent decreases in serum phosphorus were observed by Day 7 and remained relatively stable for the duration of treatment. The demonstrated reductions from baseline to Week 4 in mean serum phosphorus were significantly greater with 6 and 8 tablets/day than with 1 tablet/day (p&lt;0.0001). Mean reduction in serum phosphorus at Week 4 was 0.1 mg/dL with 1 tablet/day, 1.9 mg/dL with 6 tablets/day, and 2.1 mg/dL with 8 tablets/day.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="a472483-f897-16"></a><a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="a472483-f897-16-1"></a><a name="section-14.1"></a><p></p>
<h2>16.1	How Supplied</h2>
<p class="First">Tablets:  Auryxia 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.  The 210 mg ferric iron tablets are film-coated, peach-colored, and oval-shaped tablets embossed with â€œKX52.â€?</p>
<p>1 Bottle of 200-count 210 mg ferric iron tablets (NDC 59922-631-01)</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="a472483-f897-16-2"></a><a name="section-14.2"></a><p></p>
<h2>16.2	Storage and Handling</h2>
<p class="First">Storage:  Store at 20 to 25Â°C (68 to 77Â°F):  excursions permitted to 15Â° to 30Â°C (59Â°F to 86Â°F) [See USP controlled room temperature].  Protect from moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="a472483-f897-17"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="a472483-f897-17-1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Dosing Recommendations</h2>
<p class="First">Inform patients to take Auryxia as directed with meals and adhere to their prescribed diets. Instruct patients on concomitant medications that should be dosed apart from Auryxia.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a472483-f897-17-2"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Adverse Reactions</h2>
<p class="First">Advise patients that Auryxia may cause discolored (dark) stools, but this staining of the stool is considered normal with oral medications containing iron.</p>
<p>Auryxia may cause <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Advise patients to report severe or persistent <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> to their physician.</p>
<br><p>Manufactured for and Distributed by:</p>
<p>Keryx Biopharmaceuticals, Inc.<br>
									750 Lexington Avenue, 20th Floor<br>
									New York, NY 10022</p>
<br><p>Issued 7/2015 Rev 3.1</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SPDP1"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - NDC: 59922-631-01 - 210 mg 200-ct Bottle</span></p>
<p><img alt="Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aadd18e0-3752-11e4-8510-0800200c9a66&amp;name=keryx-figure-3.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SPDP2"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - NDC: 59922-631-91 - 210 mg 200-ct Professional Samples Bottle</span></p>
<p><img alt="Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aadd18e0-3752-11e4-8510-0800200c9a66&amp;name=keryx-figure-4.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SPDP3"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - NDC: 59922-631-92 - 210 mg 50-ct Professional Samples Bottle</span></p>
<p><img alt="Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aadd18e0-3752-11e4-8510-0800200c9a66&amp;name=keryx-figure-5.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AURYXIAÂ 		
					</strong><br><span class="contentTableReg">ferric citrate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59922-631</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TETRAFERRIC TRICITRATE DECAHYDRATE</strong> (FERRIC CATION) </td>
<td class="formItem">FERRIC CATION</td>
<td class="formItem">210Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">KX52</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59922-631-01</td>
<td class="formItem">200  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59922-631-91</td>
<td class="formItem">200  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:59922-631-92</td>
<td class="formItem">50  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205874</td>
<td class="formItem">09/17/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Keryx Biopharmaceuticals, Inc.
							(073504263)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>01ce9187-bfb9-40c1-998b-5a6e329e8816</div>
<div>Set id: aadd18e0-3752-11e4-8510-0800200c9a66</div>
<div>Version: 7</div>
<div>Effective Time: 20150814</div>
</div>
</div>Â <div class="DistributorName">Keryx Biopharmaceuticals, Inc.</div></p>
</body></html>
